Board of Directors

Ran Nussbaum – Chairman
Ran is a managing partner and co-founder of The Pontifax Group. Pontifax operates six different funds with more than 75 portfolio companies worldwide. In addition, Pontifax has established more than 19 startups since it was incorporated in 2005.

Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Currently Ran sits on the board of many of Pontifax’s portfolio companies, including Keros Therapeutics (as Chairman of the Board), Eloxx Pharmaceuticals Inc (NASDAQ: ELOX), UroGen Pharma (NASDAQ: URGN), Prevail Therapeutics (NASDAQ: PRVL) and Lutris Pharma. Previously, Ran served on the board of Kite Pharma (sold to Gilead) and cCEM Therapeutics (sold to Merck), as Chairman of the Board of OCON and NasVax, and as CEO of Spearhead and Biomedix.

Jasbir Seehra, Ph.D.
Jasbir Seehra is the founding CEO of Keros Therapeutics. Jas worked with the academic founders and Pontifax in putting together the strategy and in-licensing of the founding technology. Jas brings more than 30 years of scientific, strategic and operational experience in Biotech industry.

Prior to Keros, Dr. Seehra was the CSO at Ember Therapeutics, founded by Third Rock Ventures. In 2003, Jas co-founded Acceleron Pharma, focused on biologics inhibiting the TGFb superfamily and served as CSO to the end of 2010. Jas hired the research team that discovered multiple products and manufacturing teams and oversaw the discovery and development of multiple products targeting muscle strength, bone loss and anemia. As founder and member of the executive team, Jas helped raise more than $200M capital from venture fund and corporate partnerships with Celgene and Shire.

Jas spent 20 years at Genetics Institute and then Wyeth Pharmaceutics starting in 1983 as a bench scientist, holding numerous positions with increasing responsibility. Dr. Seehra successfully built the small molecule drug discovery capability at Genetics Institute and after the merger with Wyeth, he led the small molecule lead discovery as VP of Biological Chemistry.

He received his undergraduate and graduate degrees in Biochemistry from the University of Southampton UK. Dr. Seehra completed his postdoctoral work with Professor H. Gobind Khorana at the Massachusetts Institute of Technology. Dr. Seehra has numerous publications and is an inventor on more than 70 patents.

Julius KnowlesJay Knowles is a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare.  Partners was founded by Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH), the two principal teaching hospitals of the Harvard Medical School.  At Partners, Jay focuses on creating and helping to grow drug discovery companies. 

Prior to Partners, Jay was CEO of X-BODY Biosciences (acquired by Juno).  Previously, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations.  Jay was also President of Novalar Pharmaceuticals, a specialty pharmaceutical company that brought a drug from idea stage through the clinic and onto the market.  Before that, he was Vice President, Business Development, at Novacea and at Structural Genomix, and Director, Research and Development Planning at Vertex Pharmaceuticals.  Jay earned his MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College.  He is a member of the board of directors at Aurigene, represents Partners on the boards of Abcuro, Keros, Swan and Tilos, and is a board observer for LTI (Lysosomal Therapeutics Inc.) and Akouos.
Alon Lazarus, Ph.D.
Alon Lazarus is a Biotech Investment Manager for Arkin Holdings’ Pharma Division. He is a member of the Board of several of its pharmaceutical companies, including Oncorus, Lutris Pharma, Redpin Therapeutics and Explore Bio.

Prior to joining Arkin, Alon Lazarus worked for the Healthcare Business Development Department of Yissum – the Research & Development arm of the Hebrew University and as an analyst for the University’s Integra Holdings. Alon holds a Ph.D in Molecular Biology and an MBA – both from the Hebrew University of Jerusalem in Israel.

Tomer Kariv
Tomer has served as a member of our board of directors since January 2020. Mr. Kariv has served as Managing Partner and Co-Founder of The Pontifax Group, or Pontifax, a group of Israeli-based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies, since December 2004.

Mr. Kariv currently serves on the boards of Eloxx Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc., and he previously served on the boards of 89bio, Inc., Arno Therapeutics, Inc., Check-Cap Ltd., Macrocure Ltd. and VBI Vaccines Inc. Mr. Kariv also serves as a member of the boards of several private life sciences companies. Mr. Kariv received a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.


Zafi Avnur
In October 2016 Ms. Avnur Joined Quark Venture Inc. as Chief Scientific officer at Quark Venture Inc., a venture investment fund focused on life sciences investments. Quark Venture Inc is one of the largest global health sciences venture funds headquartered in Vancouver, Canada with offices in Boston, Hong Kong and Chengdu. The fund is diversified to invest in disruptive pre-clinical and clinical stage companies, IPOs and publicly traded companies in the areas of drug development, vaccines, diagnostics, medical devices, health IT and novel emerging convergent technologies.

Ms. Avnur was the Global Head of Academic Innovation, Roche Partnering from 2009 until October 2016. In this role she was responsible for creating relationships with the world’s leading academic institutions and world class innovators, gaining Roche early access to innovation.  Ms. Avnur has established  agreements with over 50 universities, started more than 100 academic programs in 16 locations. Ms. Avnur created the ROADS (Roche Alliance with Distinguished Scientists) program, a model for collaboration between Industry and Academic institutions.Ms. Avnur was named Global Head of Neglected Diseases Roche Partnering, establishing six collaborations and connections with non-profit organizations.Ms. Avnur found and performed scientific evaluation of opportunities and in-licensing leads mainly in early stage throughout the world. From these she has created nine startup companies. Several of these innovations were recognized as Game Changing Innovation at Roche.Preceding her current academic innovation leadership role, Ms. Avnur moved to Roche Partnering group (Basel, Switzerland, 2006) and assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas. She acted as Liaison between Pharma and Diagnostic Divisions’ Biomarkers activities, and contributed to the PHC (Personalized Health Care) initiative.Prior to her partnering roles, Ms. Avnur worked in diagnostics and pharmaceuticals research and development for nearly 20 years. She held a number of positions progressing from scientist and manager to global responsibilities. Her focus areas included diagnostics, the finding of biomarkers in various therapy areas (including Asthma and COPD, transplant genitourinary, CNS, arthritis, transplant and hepatitis C.), preclinical pharmacology (osteoporosis), overseeing the advancement of compounds from the bench into the clinic, and participate in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds.As a researcher, Ms. Avnur has participated in global committees at Roche that managed the research drug discovery portfolios for both Inflammatory and Viral Diseases. In her management roles, Ms. Avnur ran groups of up to 44 scientists.

Ms. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche.